ArticleJournal of cancer research and clinical oncology2017
Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients.
Article in Journal of cancer research and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 3 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Efficacy of traditional Chinese medicine combined with chemotherapy for gastric cancer and precancerous gastric lesions: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Pooled it
- Efficacy and safety of sodium cantharidinate and vitamin B6 injection for the treatment of digestive system neoplasms: a meta-analysis of randomized controlled trials.Drug design, development and therapy · 2019Pooled it
- Structuring healthcare advance directives: Evidence from Chinese end-of-life cancer patients' treatment preferences.Health expectations : an international journal of public participation in health care and health policy · 2023Trial
- Dauricine Mitigates Hypoxia Through Targeting ESR1, PIK3CA, and MTOR: A Network Pharmacology and Molecular Dynamics Simulation Investigation.Current issues in molecular biology · 2026Article
- Study on the correlation between seven emotions and traditional Chinese medicine syndromes, serum IL-6 and IFN-γ in patients with primary lung cancer.Clinics (Sao Paulo, Brazil) · 2026Article
- Engineered plant extracellular vesicles: Emerging nanoplatforms for combinational cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- Unlocking the Anti-Breast Cancer Potential ofCurrent issues in molecular biology · 2025Article
- Exploreing the potential mechanism of Aitongxiao formula inhibiting hepatocellular carcinoma in vitro and in vivo based on network Pharmacology.Scientific reports · 2025Article
- Protective Effect of Xihuang Pill on Immune Checkpoint Inhibitors-Related Myocarditis in a Mouse Model by Regulating the HIF-1 Signaling Pathway.Journal of inflammation research · 2025Article
- Cost analysis and cost-effectiveness of traditional Chinese medicine in lung cancer: a scoping review.Frontiers in public health · 2025Article
- Analysis of Gut Microbiota as a Diagnostic Biomarker for Lung Adenocarcinoma with Qi-Deficiency and Phlegm-Turbid Stagnation.Combinatorial chemistry & high throughput screening · 2025Article
- Associated factors, emergency department visits, and hospitalization days of receiving adjunctive Chinese herbal medicine therapy for patients with non-small cell lung cancer: a nationwide cohort study in Taiwan.Frontiers in pharmacology · 2025Article
- An Investigation of the Effect of the Traditional Naxi Herbal Formula Against Liver Cancer Through Network Pharmacology, Molecular Docking, and In Vitro Experiments.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing PDGFRB/YAP/CCN2 Axis Activity.Chinese journal of integrative medicine · 2024Article
- Using Pharmacokinetic-Pharmacodynamic Modeling to Study the Main Active Substances of the Anticancer Effect in Mice fromMolecules (Basel, Switzerland) · 2024Article
- The survival and cost-effectiveness analysis of adjunctive Chinese medicine therapy for patients with non-small cell lung cancer: a nationwide cohort study in Taiwan.Frontiers in pharmacology · 2024Article
- Network Pharmacology Analysis on the Mechanism of Xihuangwan in Treating Rectal Cancer and Radiation Enteritis.Current pharmaceutical design · 2024Article
- To Explore the Mechanism of Maiwei Dihuang Decoction in the Treatment of Non-small Cell Lung Cancer based on Network Pharmacology Combined with LC-MS.Current computer-aided drug design · 2024Article
- Comprehensive Genomic Analysis of Puerarin in Inhibiting Bladder Urothelial Carcinoma Cell Proliferation and Migration.Recent patents on anti-cancer drug discovery · 2024Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTraditional Chinese medicine is one of the popular alternative treatments for cancer, mainly enhancing host immune response and reducing adverse effect of chemotherapy. This study first explored traditional Chinese medicine treatment effect on long-term survival of lung cancer patients.
methodsThis study evaluated whether traditional Chinese medicine combined with conventional cancer treatment improved overall survival of lung cancer patients. We had conducted a retrospective cohort study on 111,564 newly diagnosed lung cancer patients in 2000-2009 from National Health Insurance Program database.
resultsA total of 23,803 (21.31%) patients used traditional Chinese medicine for lung cancer care. Eligible participants were followed up until 2011 with a mean follow-up period of 1.96 years (standard deviation 2.55) for non-TCM users and 3.04 years (2.85) for traditional Chinese medicine users. Patients with traditional Chinese medicine utilization were significantly more likely to have a 32% decreased risk of death [hazard ratio = 0.62; 95% confidence interval = 0.61-0.63], compared with patients without traditional Chinese medicine utilization after multivariate adjustment. We also observed a similar significant reduction risk across various subgroups of chronic lung diseases. Qing Zao Jiu Fei Tang was the most effective traditional Chinese medicine agent for mortality reduction both in the entire lung cancer (0.81; 0.72-0.91) and matched populations (0.86; 0.78-0.95).
conclusionThis study demonstrated adjunctive therapy with traditional Chinese medicine may improve overall survival of lung cancer patients. This study also suggested traditional Chinese medicine may be used as an adjunctive therapy for cancer treatment. These observational findings need being validated by future randomized controlled trials to rule out the possibility of effect due to holistic care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.